Prophylactic Irradiation of the Para-Aortic Lymph Nodes and Supraclavicular Lymph Nodes in Locally Advanced Uterine Cervical Cancer
This trial is active, not recruiting.
|Treatments||prophylactic irradiation of the para-aortic lymph nodes and supraclavicular lymph nodes in locally advanced uterine cervical cancer|
|Sponsor||Huazhong University of Science and Technology|
|Start date||January 2010|
|End date||February 2015|
|Trial size||200 participants|
|Trial identifier||NCT01063387, GM2010-022|
This study is an open-label, randomized study, which is designed to investigate the efficacy of Extended-field irradiation (EFI) on reducing recurrences at the para-aortic lymph node (PAN) and supraclavicular lymph nodes, and also on improving disease-free survival of locally advanced uterine cervical cancer. This study includes a translational research component in that all the primary tumors and lymph node are stained with Sema4c, before randomization. According to the investigators study result, patients with more pelvic lymph node metastasis are more likely to develop distant metastasis including the recurrences at PAN and supraclavicular lymph node. Primary cervical cancer tissues and lymph nodes are examined for expression of Sema4c just after registration, and before the patients are randomized to each arm (pelvis only vs. EFI). The investigators expect a higher benefit of EFI in patients with Sema4c-positive lymph node.
|Endpoint classification||efficacy study|
|Intervention model||parallel assignment|
To evaluate the efficacy of the Extended-Field Irradiation on the recurrence rate in para-aortic lymph nodes, supraclavicular lymph nodes and the disease-free survival rate of the patients with locally advanced uterine cervical cancer
time frame: 5 years
To evaluate overall survival, toxicities and quality of life (QOL) of the patients treated by EFI compared to the control group of patients
time frame: 5 years
Female participants from 18 years up to 80 years old.
Inclusion Criteria: - Patients (who have been adequately clinically staged) with primary, untreated, histologically confirmed invasive squamous cell carcinoma, adenocarcinoma, or adenosquamous carcinoma of the uterine cervix, FIGO stage IB1 with pelvic lymph node metastasis, IB2, IIA(≥4cm in tumor size, or pelvic LN metastasis), IIB, IIIA, IIIB? with only unilateral pelvic wall extension - Patients with negative, para-aortic lymphadenopathy determined by pelvic MRI and/or PET/CT scan. - Patients with adequate bone marrow function: ANC greater than or equal to 1,500/ul, platelets greater than or equal to 100,000/ul at the beginning. - Patients with adequate renal function: creatinine equal to or less than 2.0 mg/dL. - Patients who have signed an approved informed consent and authorization - Patients with ECOG Performance Status of 0, 1, 2 and Karnofsky Performance Scale of 100, 90, 80, 70, 60, 50 - Age: 18≤age≤80 Exclusion Criteria: - Stage IIIb with bilateral pelvic wall extension and stage IVB lesions are not eligible. - Patients with histology other than squamous, adeno, adenosquamous cell carcinoma - Patients who have received prior radiotherapy of pelvis or total hysterectomy Patients who have diagnosis of other malignant tumors other than non-malignant melanoma skin cancer or stage I. II papillary, follicular thyroid cancer.
|Official title||Molecular Markers in Lymph Node Metastasis of Cervical Cancer and Prophylactic Irradiation of the Para-Aortic Lymph Nodes and Supraclavicular Lymph Nodes in Locally Advanced Uterine Cervical Cancer|
Call for more information